[1] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
doi: 10.3322/caac.v71.3
|
[2] |
GIAQUINTO ANGELA N, HYUNA S, MILLER KIMBERLY D, et al. Breast cancer statistics, 2022[J]. CA a Cancer J Clin, 2022, 72(6): 524-541.
doi: 10.3322/caac.v72.6
|
[3] |
JIANG Y Z, MA D, SUO C, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies[J]. Cancer Cell, 2019, 35(3): 428-440.e5.
doi: 10.1016/j.ccell.2019.02.001
|
[4] |
中国医师协会精准治疗委员会乳腺癌专业委员会, 中华医学会肿瘤学分会乳腺肿瘤学组, 中国抗癌协会乳腺癌专业委员会. 中国乳腺癌患者BRCA1/2基因检测与临床应用专家共识(2018年版)[J]. 中国癌症杂志, 2018, 28(10): 787-798.
doi: 10.19401/j.cnki.1007-3639.2018.10.011
|
|
Breast cancer Professional Committee of Precision Therapy Committee of Chinese Medical Doctor Association, Breast Cancer Group of Cancer Branch of Chinese Medical Association, breast cancer Professional Committee of China Anti-Cancer Association. Expert consensus on BRCA1/2 gene detection and clinical application of breast cancer patients in China (2018 edition)[J]. China Oncol, 2018, 28(10): 787-798.
|
[5] |
KUCHENBAECKER K B, HOPPER J L, BARNES D R, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers[J]. JAMA, 2017, 317(23): 2402-2416.
doi: 10.1001/jama.2017.7112
|
[6] |
中国抗癌协会乳腺癌专业委员会, 中华医学会肿瘤学分会乳腺肿瘤学组. 中国抗癌协会乳腺癌诊治指南与规范(2024年版)[J]. 中国癌症杂志, 2023, 33(12): 1092-1187.
doi: 10.19401/j.cnki.1007-3639.2023.12.004
|
|
The Society of Breast Cancer China Anti-Cancer Association, Breast Oncology Group of the Oncology Branch of the Chinese Medical Association. Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2024 edition)[J]. China Oncol, 2023, 33(12): 1092-1187.
|
[7] |
LEE W H, BOYER T G. BRCA1 and BRCA2 in breast cancer[J]. Lancet, 2001, 358(Suppl): S5.
doi: 10.1016/S0140-6736(01)07018-0
|
[8] |
DROOGER J C, HOONING M J, SEYNAEVE C M, et al. Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: a critical review of the literature[J]. Cancer Treat Rev, 2015, 41(2): 187-196.
doi: 10.1016/j.ctrv.2014.12.002
|
[9] |
丁高峰, 郭雷鸣, 陆寓非. 乳腺癌患者HER2和BRCA1表达与放疗敏感性的关系研究[J]. 中国癌症杂志, 2021, 31(7): 589-595.
|
|
DING G F, GUO L M, LU Y F. The relationship between expressions of HER2 and BRCA1 and radiotherapy sensitivity in breast cancer patients[J]. China Oncol, 2021, 31(7): 589-595.
|
[10] |
李贺. 非小细胞肺癌患者癌组织中BRCA1和p53表达与放疗敏感性的相关性[J]. 临床医学, 2023, 43(2): 1-4.
|
|
LI H. Correlation of BRCA1 and p53 expression in cancer tissues with radiosensitivity in patients with non-small cell lung cancer[J]. Clin Med, 2023, 43(2): 1-4.
|
[11] |
SEYNAEVE C, VERHOOG L C, VAN DE BOSCH L M, et al. Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy[J]. Eur J Cancer, 2004, 40(8): 1150-1158.
pmid: 15110878
|
[12] |
BERNSTEIN J L, THOMAS D C, SHORE R E, et al. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report[J]. Eur J Cancer, 2013, 49(14): 2979-2985.
doi: 10.1016/j.ejca.2013.04.028
|
[13] |
BROEKS A, BRAAF L M, HUSEINOVIC A, et al. Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study[J]. Breast Cancer Res, 2007, 9(2): R26.
doi: 10.1186/bcr1668
pmid: 17428320
|